OncoMed Pharmaceuticals and Celgene have entered into an agreement to jointly develop and commercialize about six anti-cancer stem cell (CSC) product candidates from OncoMed's biologics pipeline, including demcizumab (OMP-21M18, Anti-DLL4). ...
Tags: clinical studies, Medicine, OncoMed
Clinical-stage company OncoMed Pharmaceuticals has announced the issuance of US patent for methods of treating cancer with its antibody vantictumab (OMP-18R5) through 2029. Targeting and inhibiting the Wnt pathway, Vantictumab was ...
Tags: Vantictumab, OncoMed